| Drug General Information |
| Drug ID |
D02GYD
|
| Former ID |
DIB007906
|
| Drug Name |
CDP-845
|
| Indication |
Cancer [ICD9: 140-229; ICD10:C00-C96]
|
Terminated |
[1]
|
|---|
| Company |
UCB Celltech
|
| CAS Number |
CAS 209164-46-5
|
| Target and Pathway |
| Target(s) |
72 kDa type IV collagenase |
Target Info |
Modulator |
[2]
|
|---|
| MMP-9 |
Target Info |
Modulator |
[2]
|
|
KEGG Pathway
|
Leukocyte transendothelial migration
|
|
GnRH signaling pathway
|
|
Estrogen signaling pathway
|
|
Pathways in cancer
|
|
Proteoglycans in cancer
|
|
Bladder cancerhsa04668:TNF signaling pathway
|
|
Hepatitis B
|
|
Transcriptional misregulation in cancer
|
|
MicroRNAs in cancer
|
|
Bladder cancer
|
|
NetPath Pathway
|
Leptin Signaling Pathway
|
|
TCR Signaling Pathway
|
|
ID Signaling PathwayNetPath_5:ID Signaling Pathway
|
|
TWEAK Signaling Pathway
|
|
TNFalpha Signaling Pathway
|
|
PANTHER Pathway
|
Alzheimer disease-presenilin pathwayP00004:Alzheimer disease-presenilin pathway
|
|
Plasminogen activating cascade
|
|
CCKR signaling map ST
|
|
Pathway Interaction Database
|
LPA receptor mediated events
|
|
Plasma membrane estrogen receptor signaling
|
|
Osteopontin-mediated events
|
|
Validated transcriptional targets of AP1 family members Fra1 and Fra2
|
|
Angiopoietin receptor Tie2-mediated signaling
|
|
Direct p53 effectors
|
|
amb2 Integrin signaling
|
|
ATF-2 transcription factor network
|
|
FOXM1 transcription factor network
|
|
Regulation of nuclear beta catenin signaling and target gene transcription
|
|
Syndecan-2-mediated signaling eventslysophospholipid_pathway:LPA receptor mediated events
|
|
Validated targets of C-MYC transcriptional activation
|
|
CXCR4-mediated signaling events
|
|
Syndecan-4-mediated signaling events
|
|
AP-1 transcription factor network
|
|
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
|
|
Syndecan-1-mediated signaling events
|
|
FGF signaling pathway
|
|
Reactome
|
Collagen degradation
|
|
Degradation of the extracellular matrix
|
|
Activation of Matrix Metalloproteinases
|
|
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
|
|
EPH-ephrin mediated repulsion of cellsR-HSA-1442490:Collagen degradation
|
|
Assembly of collagen fibrils and other multimeric structures
|
|
EPH-ephrin mediated repulsion of cells
|
|
WikiPathways
|
Activation of Matrix Metalloproteinases
|
|
AGE/RAGE pathway
|
|
Matrix MetalloproteinasesWP474:Endochondral Ossification
|
|
IL1 and megakaryotyces in obesity
|
|
Mammary gland development pathway - Involution (Stage 4 of 4)
|
|
Degradation of collagen
|
|
Spinal Cord Injury
|
|
TWEAK Signaling Pathway
|
|
Angiogenesis
|
|
Osteopontin Signaling
|
|
Matrix Metalloproteinases
|
| References |
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006498) |
|---|
| REF 2 | Clinical potential of matrix metalloprotease inhibitors. Drugs R D. 1999 Feb;1(2):117-29. |
|---|
